Biopharma Daily Stock Updates - 03/04/21

Mar 4, 2021

1 min read

$XBI $135.43 -3.22% 📉

$APLS (+0.29%) Apellis will not pursue additional development of APL-9 for severe COVID-19 source

$GLPG (+3.11%) Report primary endpoint results in MANTRA and MANTRA-Ray safety studies source

$KRON (+3.02%) Positive End-of-Phase 2 meeting with FDA for Entospletinib source

$GLYC (-2.94%) First patient dosed in China phase 1 APL-106 trial source

$LUMO (-5.82%) Published data supporting use of predictive enrichment markers for LUM-201 in Journal of the Endocrine Society source

$OCUL (-1.37%) Acceptance of sNDA for Dextenza for ocular itching associated with allergic conjunctivitis source

$ALXO (-3.15%) ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics source

$ENDP (+0.58%) Commence refinancing of existing term loan source

$SLDB (-10.72%) Inducement Grant to New Chief Legal Officer source

$AMGN (-0.91%) Amgen to acquire Five Prime Therapeutics source

$GILD (+0.77%) Gilead completes acquisition of MYR GmbH source

$RDHL (-3.35%) Closing of public offering of 4,375,000 ADSs source